复方黄黛片治疗急性早幼粒细胞白血病预算影响分析

发布时间：2018-05-02 18:07

本文选题：复方黄黛片 + 急性早幼粒细胞白血病　；参考：《中国新药杂志》2017年10期

【摘要】：目的:评估复方黄黛片纳入国家基本医保目录报销对医保基金支出可能产生的影响。方法:基于国际药物经济学与结果研究协会公布的预算影响分析指南,采用Excel构建1个跨度5年的模型。模型中,急性早幼粒细胞性白血病(acute promyelocytic leukemia,APL)患者的发病率来源文献分析;直接医疗成本等数据来源于从医疗机构采集的费用信息分析。复方黄黛片纳入医保报销的替代比例来源于专家意见。结果:复方黄黛片纳入国家医保类报销2018—2022年,砷剂费用支出分别增加359.86,719.72,1 079.58,1 439.44和1 799.30万元;医疗总费用分别少支出266.36,532.72,799.09,1 065.45和1 331.81万元;医保基金分别节省135.92,271.84,407.76,543.68和679.60万元。以APL发病率的变化、复方黄黛片纳入医保目录后替代注射砷剂比例和药品价格变动进行敏感性分析,并不改变复方黄黛片进入医保目录有利于节省医保支出的结果。结论:复方黄黛片纳入国家医保报销有利于优化资源配置。
[Abstract]:Aim: to evaluate the possible impact of compound Huangdai tablets on Medicare fund expenditure. Methods: based on the guidelines for budget impact analysis published by the International Association for Pharmacoeconomics and results Research, a 5-year model was constructed with Excel. In the model, the incidence rate of patients with acute promyelocytic leukemia (promyelocytic) was analyzed by literature analysis, and the data of direct medical cost came from the analysis of cost information collected from medical institutions. The replacement ratio of compound Huangdai tablets into medical insurance reimbursement comes from expert opinion. Results: in the period of 2018-2022, the expense of arsenic agent increased by 359.86719.7210 79.582 yuan (1 439.44 yuan) and 17.993 million yuan (RMB) respectively, the total medical expenses were 266.36532.72% 799.09 yuan (1 065.45 yuan) and 13.3181 million yuan (RMB) respectively, and the medical insurance fund saved 135.9271.8407.763.68 yuan and 6.796 million yuan respectively. According to the change of incidence of APL, the sensitivity analysis of the ratio of arsenic injection and the change of drug price after the compound Huangdai tablet was included in the catalogue of medical insurance, it did not change the result that the compound Huangdai tablet entered the catalogue of medical insurance to save the medical insurance expenditure. Conclusion: compound Huangdai tablet is beneficial to optimize the allocation of resources.
【作者单位】：北京医药卫生经济研究会;北京中医药大学管理学院;解放军第306医院;
【分类号】：R273

【相似文献】